Germany-based pharmaceutical company Merck KGaA has more than doubled the size of its corporate venturing unit to €100m ($130m).

In March 2009, Merck founded its corporate venturing unit – now branded as MS Ventures was – with €40m to invest in early-stage biotechnology companies in oncology, neurodegenerative diseases, fertility, endocrinology and cardiometabolic care. This initial fund has invested in deals, including Auxogyn, Vaximm and EpiTherapeutics.

In addition to the strategic venture fund, MS Ventures also manages the €10m MS Israel…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?